MedEdTalks

This activity is expired and is no longer available for CME credit.

PODCASTPFILDCMEABIM MOC

Dr. Nathan and Dr. Patel Discuss a Challenging Case in Treating PF-ILD

Author(s)/Faculty: Steven D. Nathan, MD; Nina M. Patel, MD
Release Date: 10/23/2020Expiration Date: 10/22/2021
Credit Type: CME / ABIM MOCNumber of Credits: 0
Content Type: PodcastProvider:
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD.